- Home
- IONS vs LCID Comparison
IONS vs LCID Comparison
Compare IONS & LCID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- LCID
- Stock Information
- Founded
- IONS 1989
- LCID 2007
- Country
- IONS United States
- LCID United States
- Employees
- IONS N/A
- LCID N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- LCID Auto Manufacturing
- Sector
- IONS Health Care
- LCID Consumer Discretionary
- Exchange
- IONS Nasdaq
- LCID Nasdaq
- Market Cap
- IONS 6.0B
- LCID 6.4B
- IPO Year
- IONS 1991
- LCID N/A
- Fundamental
- Price
- IONS $36.91
- LCID $2.78
- Analyst Decision
- IONS Buy
- LCID Hold
- Analyst Count
- IONS 18
- LCID 9
- Target Price
- IONS $62.00
- LCID $3.30
- AVG Volume (30 Days)
- IONS 1.5M
- LCID 83.1M
- Earning Date
- IONS 11-06-2024
- LCID 11-07-2024
- Dividend Yield
- IONS N/A
- LCID N/A
- EPS Growth
- IONS N/A
- LCID N/A
- EPS
- IONS N/A
- LCID N/A
- Revenue
- IONS $803,067,000.00
- LCID $730,510,000.00
- Revenue This Year
- IONS N/A
- LCID $32.75
- Revenue Next Year
- IONS $19.61
- LCID $84.89
- P/E Ratio
- IONS N/A
- LCID N/A
- Revenue Growth
- IONS 30.57
- LCID 4.98
- 52 Week Low
- IONS $33.33
- LCID $1.93
- 52 Week High
- IONS $54.44
- LCID $4.84
- Technical
- Relative Strength Index (RSI)
- IONS 52.98
- LCID 61.63
- Support Level
- IONS $36.39
- LCID $2.27
- Resistance Level
- IONS $38.90
- LCID $2.85
- Average True Range (ATR)
- IONS 1.33
- LCID 0.17
- MACD
- IONS 0.23
- LCID 0.08
- Stochastic Oscillator
- IONS 51.63
- LCID 77.23
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.